公开(公告)号：EP1762236B1

公开(公告)日：2015-07-15

申请号：EP06024671.7

申请日：2001-05-11

申请人： Septodont Holding SAS

发明人： Weber, Eckard ,  Katz, Howard I.

IPC分类号： A61K31/135 ,  A61K31/165 ,  A61K31/24 ,  A61K31/415 ,  A61K31/44 ,  A61K31/445 ,  A61K31/505 ,  A61P37/06 ,  A61P43/00

CPC分类号： A61K31/135 ,  A61K31/165 ,  A61K31/24 ,  A61K31/415 ,  A61K31/44 ,  A61K31/445 ,  A61K31/505 ,  Y10S435/81 ,  Y10S514/816 ,  Y10S514/818

公开(公告)号：EP2648520A1

公开(公告)日：2013-10-16

申请号：EP12823234.5

申请日：2012-06-18

申请人： Hospira, Inc.

发明人： ROYCHOWDHURY, Priyanka ,  CEDERGREN, Robert, A.

IPC分类号： A01N43/58 ,  A01N43/50 ,  A61K31/50

CPC分类号： A61K31/4174 ,  A61K9/0019 ,  A61K9/08 ,  A61K31/4164 ,  A61K47/02 ,  A61L2/0023 ,  A61P9/12 ,  A61P23/02 ,  A61P25/20 ,  A61P25/22 ,  A61P29/00 ,  Y10S514/816

摘要： The presently disclosed subject matter relates to pharmaceutical compositions comprising dexmedetomidine or a pharmaceutically acceptable salt thereof wherein the composition is formulated as a liquid for parenteral administration to a subject, and wherein the composition is disposed within a sealed container as a premixture. The pharmaceutical compositions can be used, for example, in perioperative care of a patient or for sedation.

摘要翻译： 药物组合物包含右美托咪定或其药学上可接受的盐，其中所述组合物配制成用于肠胃外施用于受试者的液体，并且其中所述组合物作为预混合物置于密封容器内。 该药物组合物可以用于患者的围手术期护理或镇静。

公开(公告)号：EP1448666B1

公开(公告)日：2008-09-10

申请号：EP02789694.3

申请日：2002-11-15

申请人： AP Pharma, Inc.

发明人： NG, Steven, Y. ,  HELLER, Jorge

IPC分类号： C08G65/34 ,  C08G65/00 ,  C08G63/664 ,  A61K47/00

CPC分类号： C08G63/668 ,  C08G65/002 ,  C08G65/34 ,  C08G2650/42 ,  Y10S514/816 ,  Y10S514/817 ,  Y10S514/887

摘要： Bioerodible poly(ortho esters) useful as orthopedic implants or vehicles for the sustained delivery of pharmaceutical, cosmetic and agricultural agents contain amine functionalities and α-hydroxy acid-containing groups. Block copolymers contain these bioerodible poly (ortho esters). These block copolymers have both hydrophilic and hydrophobic blocks. They form micelles in aqueous solution, making them suitable for encpasulation or solubilization of hydrophobic or water-insoluble materials; and they also form bioerodible matrices for the sustained release of active agents.

公开(公告)号：EP1200103B1

公开(公告)日：2008-08-13

申请号：EP00948171.4

申请日：2000-07-28

申请人： Protexeon Limited

发明人： FRANKS, Nicholas P. Biophysics Sec., BlackettLab. ,  MAZE, Mervyn Dept. Anaesthetics, Imperial College

IPC分类号： A61K33/00 ,  A61P25/28 ,  A61P25/36

CPC分类号： A61K33/00 ,  Y10S514/812 ,  Y10S514/816 ,  Y10S514/959

摘要： The present invention relates to the use of xenon as a neuroprotectant and/or as an inhibitor of synaptic plasticity. In a preferred aspect, the xenon acts as an NMDA antagonist. The present invention also provides a method of reducing the level of activation of the NMDA receptors in a mammal, the method comprising modulating the activity of the NMDA receptor by administering to the mammal a therapeutically effective amount of xenon, wherein said reduction achieves neuroprotection and/or an inhibition of synaptic plasticity. A further embodiment of the invention provides a pharmaceutical composition for providing neuroprotection and/or inhibition of synaptic plasticity, together with a process for the process for the preparation thereof.

摘要翻译： 本发明涉及氙作为神经保护剂和/或作为突触可塑性抑制剂的用途。 在优选的方面，氙充当NMDA拮抗剂。 本发明还提供了降低哺乳动物NMDA受体活化水平的方法，所述方法包括通过向哺乳动物施用治疗有效量的氙来调节NMDA受体的活性，其中所述减少实现神经保护和/ 或抑制突触可塑性。 本发明的另一个实施方案提供用于提供神经保护和/或抑制突触可塑性的药物组合物，以及其制备方法。

公开(公告)号：EP1256344B1

公开(公告)日：2006-12-20

申请号：EP00970160.8

申请日：2000-10-27

申请人： Astellas Pharma Inc.

发明人： YUYAMA,Hironori Yamanouchi Pharmaceutical Co.,Ltd. ,  FUJIMORI, Akira Yamanouchi Pharmaceutical Co.,Ltd. ,  SANAGI, Masanao Yamanouchi Pharmaceutical Co.,Ltd. ,  HARADA,Hironori Yamanouchi Pharmaceutical Co.,Ltd. ,  KOAKUTSU, Akiko Yamanouchi Pharmaceutical Co.,Ltd. ,  MORI, Mikiko Yamanouchi Pharmaceutical Co., Ltd. ,  YAMAMOTO,Nobuyuki Yamanouchi Pharmaceutical Co.Ltd

IPC分类号： A61K31/505 ,  A61P35/00 ,  C07D239/46 ,  A61P29/02

CPC分类号： A61K31/506 ,  C07D239/46 ,  C07D239/52 ,  Y10S514/816 ,  Y10S514/817 ,  Y10S514/818 ,  Y10S514/825 ,  Y10S514/883 ,  Y10S514/908

摘要： Drug compositions for treatment of prostatic cancer, containing as the active ingredient N-[6-methoxy-5-(2-methoxyphenoxy)-2-(2-pyrimidinyl)-4-pyrimidinyl]-2-phenyl- ethenesulfonamide or pharmaceutically acceptable salts thereof.

公开(公告)号：EP1713444A1

公开(公告)日：2006-10-25

申请号：EP05713453.8

申请日：2005-02-14

申请人： BIOAVAILABILITY, INC.

发明人： HARRIS, Steven, B. ,  HUANG, Nick, J.

IPC分类号： A61K9/113 ,  A61K31/05

CPC分类号： A61K9/1075 ,  A61K9/0019 ,  A61K31/05 ,  A61K47/10 ,  A61K47/14 ,  Y10S514/816

摘要： The invention provides a method and a composition for enhancing the dissolution and bioavailable properties of propofol (2, 6 diisopropyl phenol) for use as an intravenously administered anesthetic in mammals. The method produces a self-microemulsifyable emulsion base composition that is utilized in the production of a water-based microemulsiori preparation. In a preferred two (2) component base composition, the base composition consists of: a surfactant, containing polyethylene glycol; and liquid propofol. The microemulsion is prepared by mixing the base composition with a carrier liquid, which results in the formation of a microemulsion containing concentrations of propofol of up to about 4% by weight of propofol to the volume of the microemulsion. In a four (4) component base composition, the base composition consists of: a surfactant, containing polyethylene glycol; liquid propofol; a water-immiscible solvent; and ethanol. The microemulsion is prepared by mixing the base composition with a carrier liquid, which results in the formation of a microemulsion containing concentrations of propofol of up to about 10% by weight of propofol to the volume of the microemulsion.

公开(公告)号：EP1105096B1

公开(公告)日：2003-10-29

申请号：EP99942292.6

申请日：1999-08-18

申请人： SKYEPHARMA CANADA INC.

发明人： MISHRA, Awadhesh K. ,  PACE, Gary W. ,  VACHON, Michael, G.

IPC分类号： A61K9/107 ,  A61K31/05

CPC分类号： A61K9/1075 ,  A61K9/0019 ,  A61K31/05 ,  A61K47/14 ,  A61K47/24 ,  A61K47/28 ,  Y02A50/473 ,  Y10S514/816 ,  Y10S514/817 ,  Y10S514/818 ,  Y10S514/938

摘要： Irritation upon injection of a formulation containing propofol is reduced or substantially eliminated by administering a stable, sterile, and antimicrobial aqueous dispersion comprising a water-insoluble microdroplet matrix of mean diameter from about 50 nm to about 1000 nm consisting essentially of about 1% to about 15% of propofol, up to about 7% of a propofol-soluble diluent, and about 0.8% to about 4% of a surface stabilizing amphiphilic agent. The aqueous phase includes a pharmaceutically acceptable water-soluble polyhydroxy tonicity modifier. The propofol-containing dispersion is devoid of additional bactericidal or bacteriostatic preservative agents.

公开(公告)号：EP1256344A1

公开(公告)日：2002-11-13

申请号：EP00970160.8

申请日：2000-10-27

申请人： YAMANOUCHI PHARMACEUTICAL CO. LTD.

发明人： YUYAMA,Hironori Yamanouchi Pharmaceutical Co.,Ltd. ,  FUJIMORI, Akira Yamanouchi Pharmaceutical Co.,Ltd. ,  SANAGI, Masanao Yamanouchi Pharmaceutical Co.,Ltd. ,  HARADA,Hironori Yamanouchi Pharmaceutical Co.,Ltd. ,  KOAKUTSU, Akiko Yamanouchi Pharmaceutical Co.,Ltd. ,  MORI, Mikiko Yamanouchi Pharmaceutical Co., Ltd. ,  YAMAMOTO,Nobuyuki Yamanouchi Pharmaceutical Co.Ltd

IPC分类号： A61K31/505 ,  A61P35/00

CPC分类号： A61K31/506 ,  C07D239/46 ,  C07D239/52 ,  Y10S514/816 ,  Y10S514/817 ,  Y10S514/818 ,  Y10S514/825 ,  Y10S514/883 ,  Y10S514/908

摘要： A pharmaceutical composition for therapeutically treating prostate cancer, the pharmaceutical composition containing N-[6-methoxy-5-(2-methoxyphenoxy)-2-(2-pyrimidinyl)-4-pyrimidinyl]-2-phenylethenesulfoneamide or a pharmaceutically acceptable salt thereof as the effective component.

摘要翻译： 一种用于治疗前列腺癌的药物组合物，所述药物组合物含有N-6-甲氧基-5-（2-甲氧基苯氧基）-2-（2-嘧啶基）-4-嘧啶基] -2-乙基乙烯基磺酰胺或其药学上可接受的盐作为 有效成分。

公开(公告)号：EP1187635A1

公开(公告)日：2002-03-20

申请号：EP00940519.2

申请日：2000-06-09

申请人： IMPERIAL COLLEGE OF SCIENCE,TECHNOLOGY & MEDICINE

发明人： FRANKS, Nicholas PeterImperial College Science ,  MAZE, MervynImperial Coll.School of Med.

IPC分类号： A61K45/06 ,  A61K33/00 ,  A61K31/4174 ,  A61P23/00

CPC分类号： A61K33/00 ,  Y10S514/816 ,  Y10S514/817 ,  Y10S514/818 ,  A61K31/415 ,  A61K2300/00

摘要： A pharmaceutical composition is described. The composition comprises a formulation. The formulation comprises an NMDA antagonist and an alpha 2 adrenergic agonist. In a preferred aspect, there is provided an improved anaesthetic comprising an NMDA antagonist and an alpha-2 adrenergic agonist.

公开(公告)号：EP1181030A2

公开(公告)日：2002-02-27

申请号：EP00940292.6

申请日：2000-05-31

申请人： INDENA S.p.A.

发明人： BOMBARDELLI, Ezio ,  MORAZZONI, Paolo

IPC分类号： A61K35/78

CPC分类号： A61K36/28 ,  A61K8/97 ,  A61Q19/00 ,  Y10S514/816 ,  Y10S514/885

摘要： Extracts of Tanacetum parthenium with a reduced content of α-unsaturated η-lactons, particularly of parthenolide, obtainable by elution on basic resins. The extracts of the invention have favourable pharmacological properties together with reduced risks of allergic reactions.